Solanezumab is the new drug from the company Eli Lilly which was originally studied back in 2012 and was being considered as a revolutionary treatment of dementia. Its mode of action involves trying to attack the damaged proteins (known as amyloid) which cause Alzheimer’s dementia. Data suggests Solanezumab may work in the early stages of the disease to slow its progression. It is thus now talked about as the first “disease-modifying” drug available for dementia. Thus far research has been disappointing in finding a medication which could slow down dementia so this is a potentially exciting development.